From: Allergy clinics in times of the SARS-CoV-2 pandemic: an integrated model
Recommendations in non COVID-19 individuals |
---|
Interrupting subcutaneous immunotherapy is not advised. Especially in potentially life-threatening allergies, such as venom allergy, SCIT should be regularly continued. The possibility of expanding injection intervals in the continuation phase should be checked and may be beneficial |
Interrupting sublingual immunotherapy is not advised. Supply the patient with sufficient medication for a minimum of 14 days isolation |
Sublingual immunotherapy can be taken at home. The intake of SLIT by the patient at home or any place is advantageous in avoiding contact with potentially infected persons |
Both subcutaneous and sublingual immunotherapy can be continued in the current COVID-19 pandemics, in any asymptomatic patient without suspicion for SARS-CoV-2 infection and/or contact with SARS-CoV-2 positive individuals, in any patient with negative test result (RT-PCR) or in any patient after an adequate quarantine or with detection of serum IgG to SARS-CoV-2 without virus-specific IgM |
Preparedness of your Allergy clinic is imperative to cope with COVID-19. Follow World Health Organization (WHO) guidelines and advice staff accordingly |
These recommendations are conditional since there is paucity of data and they should be revised regularly with incoming new information on COVID-19 |
Recommendations in COVID-19 diagnosed cases or suspicion for SARS-CoV-2 infection |
---|
Interrupting subcutaneous immunotherapy is advised |
Interrupting sublingual immunotherapy is advised |
Both subcutaneous and sublingual immunotherapy should be discontinued in symptomatic patients with exposure or contact with SARS-CoV-2 positive individuals, or patients with positive test results (RT-PCR) |